Core Insights - Genenta Science and ANEMOCYTE have announced a strategic collaboration focusing on off-the-shelf lentiviral vector (LVV) Plasmid DNA technology, expanding their existing partnership in plasmid DNA production [1][3] - The collaboration aims to leverage Genenta's established LVV Plasmid DNA technology, enhancing ANEMOCYTE's offerings to clients by providing high-quality materials from R&D to GMP grade [2][3] - This partnership signifies a commitment to supporting the life science industry with innovative solutions, ensuring clients have access to a reliable platform for advanced therapy programs [3] Company Profiles - Genenta Science is a clinical-stage immuno-oncology company developing a proprietary hematopoietic stem cell therapy for various solid tumor cancers, with its first-in-class product candidate, Temferon™, designed to express immune-therapeutic payloads within the tumor microenvironment [5] - ANEMOCYTE is a Biotech Manufacturing Organization based in Italy, specializing in the development and manufacturing of pDNA and mRNA, with over 25 years of expertise in innovative therapies [4]